drugset / Trial / NCT00627003

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

NCT00627003

Phase 3 Completed 43 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS. Also, additional objective and subjective sleep parameters and quality of life will be assessed.

Timeline

Start
2002-11
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule 2 mg Oral